FOLH1 and prostate neoplasm: Positron Emission Tomography/Computed Tomography (PET/CT), combining functional and anatomical information with the use of radionuclides targeting the prostate-specific membrane antigen (PSMA), is established for primary staging in prostate tumors with high-risk features, and for biochemical relapse (BCR) or persistence (BCP) [1,2].